

## Swissmedic Regulatory Training, Spring 2026 AGENDA

### Module 1 Introduction (all groups)

Day 1: Monday, 8 June 2026

Room H044

<i>Time</i>	<i>Topic</i>	<i>Speaker / Moderator</i>
08:45	<b>Start Day 1</b>	
08:45	Arrival and Registration at Facility Hallerstrasse 7	All
09:00–09:05	Welcome address	Vincenza Trivigno <i>Executive Director, Swissmedic</i>
09:05–09:15	Opening remarks	Hiiti Sillo <i>Unit Head, Regulation and Safety, WHO</i>
09:15–09:45	General information and presentation of agenda  Group introduction	Lodovico Paganini <i>Deputy Head Stakeholder Engagement</i>  All
09:45–10:30	Introduction Swissmedic <ul style="list-style-type: none"> <li>Context and figures</li> <li>Role and Responsibility</li> </ul>	Jörg Schläpfer <i>Head of Sector Staff and External Relations</i>
10:30–10:45	<b>Group photo and coffee break</b>	
10:45–11:15	Overview Swissmedic: National and International cooperation	Gabriela Zenhäusern <i>Head of Division Stakeholder Engagement</i>
11:15–12:00	Introduction to Swissmedic's Horizon Scanning	Daniel Hürlimann <i>Scientific Officer Innovation Management, Corporate Development</i>
12:00–13:00	<b>Lunch @ Cafeteria Swissmedic Hallerstrasse 7</b>	
13:00–13:45	Overview of WHO Regulatory Systems Strengthening Programme <ul style="list-style-type: none"> <li>Capacity building activities</li> <li>WHO Role during the pandemic</li> </ul>	Razieh Ostad Ali <i>Scientist, Regulatory Systems Strengthening Team, Regulation and Safety Unit, WHO</i>
13:45–14:30	Good reliance practices in regulatory decision-making high-level principles and recommendations	Sunday Kisoma <i>Technical Officer, Facilitated Product Introduction, Regulation and Safety, WHO</i>
14:30–15:00	<b>Coffee break</b>	
15:00–16:15	Good regulatory practices and QMS guidelines for national regulatory authorities for medical products	Alireza Khadem <i>Team Lead, Regulatory Systems Strengthening Team, WHO</i>
16:15–17:00	WHO Global Model Regulatory Framework for Medical Devices and GBT+	Agnes Kijo, <i>Technical Officer, Regulation and Safety Unit, WHO</i>
17:00–17:30	Q&A	
	<b>End of Day 1</b>	

## Module 3 Authorisations

Day 2: Tuesday, 9 June 2026

Room H048

<i>Time</i>	<i>Topic</i>	<i>Speaker / Moderator</i>
09:30	<b>Start Day 2</b>	
09:30–10:30	<b>Marketing Authorisation and Regulatory Management</b> <ul style="list-style-type: none"> <li>• Introduction Marketing Authorisation</li> <li>• Processes incl. risk-based approaches and reliance</li> <li>• Swiss Medical Expert committee</li> <li>• Benchmarking</li> </ul>	Rosa Stebler <i>Deputy Head of Division, Regulatory Operations and Development</i>  Gierin Thomi <i>Responsible for Expert Affairs</i>
10:30–11:00	<b>Coffee break</b>	
11:00–12:00	<b>Marketing Authorisation and Regulatory Management</b> (continued) Q&A / Discussion	
12:00–13:00	<b>Lunch @ Facility Hallerstrasse</b>	
13:00–14:30	Introduction <b>Regulatory Assessment</b>	Chantal Walther <i>Head of Unit Regulatory Assessment 4</i>
14:30–15:00	<b>Coffee break</b>	
15:00–16:30	Introduction <b>Quality Assessment</b>  MA Procedures for <b>Biosimilar Applications</b> in Switzerland	Lisa Esenbeiss <i>Quality Assessor</i>  Pascal Crottet <i>Quality Assessor</i>
16:30	<b>End of Day 2</b>	
16:30	<b>Social Event (on site)</b>	

## Module 3 Authorisations

Day 3: Wednesday, 10 June 2026

Room H48

<i>Time</i>	<i>Topic</i>	<i>Speaker / Moderator</i>
09:00	<b>Start Day 3</b>	
09:00–10:30	Introduction <b>Non-Clinical Assessment</b>	Elisabeth Klenke <i>Head of Division Non-Clinical Assessment</i>
10:30–10:45	<b>Coffee break</b>	
10:45–12:30	Introduction <b>Clinical Assessment</b> (Part 1) Generics	Arno Nolting <i>Senior Clinical Pharmacology Assessor</i> Andrea Villiger <i>Clinical Pharmacology Assessor</i>
12:30–13:30	<b>Lunch @ Facility Hallerstrasse</b>	
13:30–15:00	Introduction <b>Clinical Assessment</b> (Part 2) Case study: Step-by-step assessment report template	Jan Wagner <i>Senior Clinical Assessor</i> Alain Bizzini <i>Clinical Assessor</i>
15:00–15:30	<b>Coffee break</b>	
15:30–16:30	<b>Introduction to Clinical Study Assessment</b>	Kirsten Leidreiter <i>Head Clinical Study Assessment</i>
16:30	<b>End of Day 3</b>	

## Module 3 Authorisations

Day 4: Thursday, 11 June 2026

Room F032

<i>Time</i>	<i>Topic</i>	<i>Speaker / Moderator</i>
09:00	<b>Start Day 4</b>	
08:45 09:00	Meeting at Hallerstrasse ➔ Transfer to Freiburgstrasse 139	Lodovico Paganini <i>Scientific Officer Stakeholder Engagement</i>
09:00–10:00	Introduction to <b>Advanced Therapeutic Medicinal Products</b> <ul style="list-style-type: none"> <li>- General information ATMPs</li> <li>- Requirements on documentation for MA</li> </ul>	Julia Djonova <i>Head of Division Advanced Therapy Medicinal Products</i>
10:00–10:30	<b>Coffee break</b>	
10:30–12:00	Swissmedic collaborative <b>Marketing Authorisation and Scientific Advice Procedure</b> for Global Health products (MAGHP/SAGHP)	Lodovico Paganini <i>Scientific Officer Stakeholder Engagement</i>
12:00–13:30	<b>Lunch @ Facility Freiburgstrasse</b>	
	Optional program in the afternoon: <ul style="list-style-type: none"> <li>- Participation in session on MD (Modul 4)</li> <li>- Preparation of country presentation</li> <li>- Individual study time (room F032)</li> </ul>	
	<b>End of Day 4</b>	

## Module 5: End module (All groups)

Day 5, Friday, 12 June 2026

Room EU137

09:00	<b>Start Day 5</b>	
9:00–10:30	NRAs country presentation of Lessons Learned (10 min presentation plus 10 min discussion)	All
10:45–11:00	<b>Coffee break</b>	
11:00–12:00	Wrap-up and closing remarks	Swissmedic and WHO representatives
12:00–13:30	<b>Lunch @ Facility Hallerstrasse</b>	
	<b>End of Day 5 / End of Training</b>	